Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00459173




Registration number
NCT00459173
Ethics application status
Date submitted
10/04/2007
Date registered
11/04/2007
Date last updated
7/04/2009

Titles & IDs
Public title
Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation
Scientific title
Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Maintenance of Smoking Cessation (1-Year Treatment, 1-Year Follow-up)
Secondary ID [1] 0 0
EFC4796
Universal Trial Number (UTN)
Trial acronym
STRATUS-WW
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Maintenance of Smoking Cessation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - rimonabant (SR141716)

Treatment: Drugs: rimonabant (SR141716)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to smoking relapse from the point of re-randomization (Week 10) through Week 32
Timepoint [1] 0 0
Primary outcome [2] 0 0
Smoking relapse defined as: any 7 or more consecutive days of smoking (even a puff) or any 2 consecutive days of smoking 5 or more cigarettes per day
Timepoint [2] 0 0
Secondary outcome [1] 0 0
Efficacy: Time to smoking relapse from Week 10 to Week 52, craving, body weight change in abstainers, lipid parameters
Timepoint [1] 0 0
Secondary outcome [2] 0 0
Safety data
Timepoint [2] 0 0

Eligibility
Key inclusion criteria
- Smokers smoking at least 10 cigarettes/day as a mean within the 2 months preceding the
screening visit

- Motivated to quit with a score greater than or equal to 6 on the ten-point Motivation
Scale
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- non tobacco cigarettes consumption

- chronic use of marijuana

- pregnancy, breastfeeding

- any clinically significant disease that might interfere with the efficacy or safety
evaluation of the study drug

- Concomitant use of drugs as an aid to smoking cessation or that might induce weight
change

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2002
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2005
Sample size
Target
Accrual to date
Final
4850
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Sanofi-Aventis - Cove
Recruitment postcode(s) [1] 0 0
- Cove
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New Jersey
Country [2] 0 0
Canada
State/province [2] 0 0
Quebec

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg
and 20 mg) for the maintenance of abstinence from smoking.

Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the
clinical and biological safety of 2 doses of rimonabant rimonabant during a 12-month
treatment period and to evaluate the pharmacokinetics of the drug.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00459173
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ICD CSD
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00459173